5 results match your criteria: "Iwasawa Clinic[Affiliation]"
Efficacy and safety of desmopressin orally disintegrating tablets 25 and 50 μg in male patients with nocturia: A Japanese real-world multicenter clinical study.
Low Urin Tract Symptoms
November 2022
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Article Synopsis
- The study aimed to evaluate the effectiveness of desmopressin orally disintegrating tablets (ODT) in reducing nighttime urination (nocturia) in male patients while analyzing factors that predict improvements.
- Conducted at 27 institutions in Japan, the research included 118 male patients and found a persistence rate of about 51.3% after 12 weeks, with many discontinuing treatment due to adverse events, primarily hyponatremia.
- Results showed significant reductions in nighttime frequency of urination, particularly for patients with larger nighttime urine volumes, indicating that desmopressin ODT is useful for male patients with nocturnal polyuria in real-world settings.
Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Int J Urol
October 2018
Department of Urology, JCHO Hokkaido Hospital, Sapporo, Hokkaido, Japan.
Objective: To assess the efficacy of silodosin as second-line α-blocker monotherapy in patients with lower urinary tract symptoms as a result of benign prostatic hyperplasia.
Methods: Men who were given an α-blocker other than silodosin for ≥8 weeks, aged ≥50 years, had a total International Prostate Symptom Score ≥13 and quality of life index ≥4 were enrolled. After treatment with 8 mg/day silodosin for 8 weeks, symptoms and treatment satisfaction were assessed.
Purpose: Our aim was to prospectively analyze the 3-year outcomes of naftopidil treatment for patients with benign prostatic hyperplasia (BPH), including those who dropped out during follow-up and had retreatment for BPH after termination of the drug within 3 years.
Patients And Methods: Naftopidil, 50 mg/d or 75 mg/d, was given to 117 patients having BPH aged 50 years and older who had international prostate symptom scores (IPSS) ≥8. They were prospectively followed for 3 years with periodic evaluation.
A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
J Urol
March 2015
Department of Urology, Hokkaido Prefectural Esashi Hospital, Hokkaido, Japan.
Purpose: We evaluated the efficacy and safety of add-on treatment with a β3-adrenoceptor agonist (mirabegron) for overactive bladder symptoms remaining after α1-blocker (tamsulosin) treatment in men with benign prostatic obstruction.
Materials And Methods: Patients with benign prostatic obstruction with urinary urgency at least once per week and a total OABSS of 3 or more points after 8 or more weeks of treatment with tamsulosin were enrolled in the study. They were randomly allocated to receive 0.
Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis.
Antibiotics (Basel)
April 2014
Department of Urology, Fuji City General Hospital, 50 Takashima-Cho, Fuji, Shizuoka 4178567, Japan.
Article Synopsis
- A clinical trial conducted from 2011-2013 evaluated the effectiveness of a single 2 g oral dose of azithromycin extended-release in treating urethritis in heterosexual males, showing a 90.9% eradication rate in patients with gonococcal urethritis.
- The study found that Neisseria gonorrhoeae strains showed strong susceptibility to various antibiotics, with azithromycin having a lower susceptibility rate at 37.2%.
- While the treatment was largely effective (90% eradication rate for nongonococcal urethritis), the main side effect was temporary diarrhea, and ongoing monitoring of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma